Efficacy and Safety of Nevirapine Extended-Release Once Daily versus Nevirapine Immediate-Release Twice-Daily in Treatment-Naive HIV-1-Infected Patients

Abstract

Background

This study (VERxVE) compared the efficacy and safety of the new nevirapine extended-release (NVP XR) formulation dosed once daily with NVP immediate release (IR) twice daily in treatment-naive patients.

Methods

Randomized, double-blind, double-dummy, parallel group study of HIV-1-infected adult patients with baseline viral load (VL) ≥1,000 copies/ml and CD4⁺ T-cell count of >50-<400 (males) and >50-<250 cells/mm³ (females). Patients stratified by baseline VL (≤100,000/>100,000 copies/ml) were randomized 1:1 to NVP XR 400 mg once daily (plus placebo) or NVP IR 200 mg twice daily (plus placebo), both combined with tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine 200 mg once daily. Primary endpoint was sustained virological response (<50 copies/ml) through week 48 using the time to loss of virological response algorithm. Non-inferiority of NVP XR to NVP IR was tested using Cochran's statistic incorporating baseline VL stratum with pre- specified, non-inferiority margin of -10%.

Results

Among 1,011 patients randomized and treated, virological response at week 48 was 81.0% (409/505) for NVP XR and 75.9% (384/506) for NVP IR with adjusted difference of 4.9% in favour of NVP XR (95% CI -0.1– 10.0%), demonstrating non-inferiority of NVP XR to NVP IR. This finding was supported by secondary endpoints. The safety profile of NVP XR was similar to NVP IR, but showed numerically fewer treatment-related adverse events.

Conclusions

NVP XR in combination with TDF and emtricitabine was shown to be non-inferior in efficacy to NVP IR with a similar safety and adverse event pro-file, with the potential for the added convenience of once-daily dosing. Trial registration: ClinicalTrials (NCT): NCT00561925.

References

European AIDS Clinical Society. European guidelines for the clinical management and treatment of HIV infected adults (version 5.3). (Updated 11 November 2009. Accessed 30 November 2010.) Available from http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf.

Thompson

M.A.

, Aberg

J.A.

, Cahn

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321–333.

DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 10 January 2011. Accessed 28 April 2011.) Available from http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf.

Phillips

A.N.

, Pradier

, Lazzarin

Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001; 15: 2385–2395.

Cozzi-Lepri

, Phillips

A.N.

, d'Arminio Monforte

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. J Infect Dis 2002; 185: 1062–1069.

van Leth

, Phanuphak

, Ruxrungtham

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253–1263.

Viramune^® E.U. Summary of product characteristics. Boehringer Ingelheim. Available from www.medicines.org.UK/emc/medicine/322/spc/viramune+200mg+Tablets/.

Soriano

V.A.K.

, Migrone

, Lutz

Nevirapine versus Atazanavir/ritonavir, each combined with Tenofovir/ Emtricitabine, in antiretroviral-naive HIV-1 patients: week 48 ARTEN results. Antivir Ther 2011; 16: 339–348.

McIntyre

, Hughes

, Mellors

Efficacy of ART with NVP_TDF/FTC vs LPV/r_TDF/FTC among antiretroviral-naive women in Africa: OCTANE Trial. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 1S3LB.

10.

Merluzzi

V.J.

, Hargrave

K.D.

, Labadia

Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250: 1411–1413.

11.

Joly

, Yeni

Non-nucleoside reverse transcriptase inhibitors. Ann Med Interne (Paris) 2000; 151: 260–267.

12.

Waters

, John

, Nelson

Non-nucleoside reverse transcriptase inhibitors: a review. Int J Clin Pract 2007; 61: 105–118.

13.

van Leth

, Huisamen

C.B.

, Badaro

Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. J Acquir Immune Defic Syndr 2005; 38: 296–300.

14.

Battegay

M.E.

, Arasteh

, Plettenberg

Assessment of the steady-state PK parameters of two extended release (XR) nevirapine (NVP) tablets 400 mg and 300 mg QD compared with immediate release (IR) NVP tablets 200 mg BID in HIV-1-infected patients - the ERVIR study (P09-14707). HIV Med 2009; 10 Suppl 2: 76–77.

15.

Hawkins

, Geist

, Young

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005; 6: 187–196.

16.

Gazzard

B.G.

, Anderson

, Babiker

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563–608.

17.

Sáez-Llorens

, Violari

, Deetz

C.O.

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22: 216–223.

18.

van Rossum

A.M.

, Geelen

S.P.

, Hartwig

N.G.

Results of 2 years of treatment with protease-inhibitor–containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002; 34: 1008–1016.

19.

Mills

E.J.

, Bakanda

, Birungi

Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. Aids 2011; 25: 851–855.

20.

FDA. Guidance for industry antiretroviral drugs using plasma HIV RNA measurements – clinical considerations for accelerated and traditional approval. (Updated October 2002. Accessed February 2011.) Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf.

21.

Lima

, Harrigan

, Montaner

J.S.

Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009; 51: 3–6.

22.

Pav

J.W.

, Rowland

L.S.

, Korpalski

D.J.

HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. J Pharm Biomed Anal 1999; 20: 91–98.

23.

Rowland

L.S.

, MacGregor

T.R.

, Campbell

S.J.

, Jenkins

, Pearsall

A.B.

, Morris

J.P.

Quantitation of five nevirapine oxidative metabolites in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 856: 252–260.

24.

Monogram Biosciences. Phenosense. (Updated 2010. Accessed 27 April 2011.) Available from http://www.monogramvirology.com/hiv-tests/resistance-testing/phenotype/phenosense/.

25.

Cochran

Some methods for strengthening the common chi squared test. Biometrics 1954; 10: 417–451.

26.

Rey

, Hoen

, Chavanet

High rate of early virological failure with the once-daily tenofovir/lamivudine/ nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 380–388.

27.

Resino

, Bellon

J.M.

, Munoz-Fernandez

M.A.

Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J Antimicrob Chemother 2006; 57: 579–582.

28.

Johnson

V.A.

, Brun-Vezinet

, Clotet

Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17: 138–145.

29.

Arasteh

, Ward

, Plettenberg

24 Week efficacy and safety of switching virologically stable HIV-1 patients from nevirapine IR 200mg BID to nevirapine XR 400mg QD. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 12–15 September 2010, Boston, MA, USA. Poster H-207.

30.

Arasteh

, Ward

, Plettenberg

48 Week efficacy and safety of switching virologically stable HIV-1 patients from nevirapine IR 200mg BID to nevirapine XR 400mg QD. 10th International Congress on Drug Therapy in HIV infection (HIV10). 7–11 November 2010, Glasgow, UK. Poster P45.